-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on IDEAYA Biosciences, Lowers Price Target to $45

Benzinga·11/04/2026 16:53:27
Listen to the news
RBC Capital analyst Leonid Timashev maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Outperform and lowers the price target from $48 to $45.